# Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

> **NCT05451771** · PHASE1,PHASE2 · RECRUITING · sponsor: **Rajshekhar Chakraborty, MD** · enrollment: 53 (estimated)

## Conditions studied

- AL Amyloidosis

## Interventions

- **DRUG:** Venetoclax Oral Tablet, 200 mg
- **DEVICE:** FISH assay
- **DRUG:** Venetoclax Oral Tablet, 400 mg
- **DRUG:** Dexamethasone Oral, 10 mg
- **DRUG:** Dexamethasone Oral, 20 mg
- **DRUG:** Daratumumab Injection
- **DRUG:** Bendamustine
- **DRUG:** Pomalidomide
- **DRUG:** Ixazomib
- **DRUG:** Venetoclax MTD with Dexamethasone

## Key facts

- **NCT ID:** NCT05451771
- **Lead sponsor:** Rajshekhar Chakraborty, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-10-26
- **Primary completion:** 2026-09
- **Final completion:** 2026-09
- **Target enrollment:** 53 (ESTIMATED)
- **Last updated:** 2025-07-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05451771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05451771, "Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05451771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*